<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>Capy Guidebook</title><id>https://dosepace.pages.dev/learn/</id><updated>2026-09-03T00:00:00Z</updated><link href="https://dosepace.pages.dev/feed.xml" rel="self"/><author><name>Capy Editorial Team</name></author><entry xml:lang="en-US"><title>What to Track During GLP-1 Treatment</title><id>https://dosepace.pages.dev/learn/what-to-track-during-glp-1-treatment/</id><link href="https://dosepace.pages.dev/learn/what-to-track-during-glp-1-treatment/"/><updated>2026-09-03T00:00:00Z</updated><author><name>Capy Editorial Team</name></author><summary>A practical, non-prescriptive checklist for organizing GLP-1 doses, symptoms, weight, nutrition, and questions before a healthcare appointment.</summary></entry><entry xml:lang="en-US"><title>Mounjaro vs. Zepbound in 2026: Same Ingredient, Different FDA-Labeled Uses</title><id>https://dosepace.pages.dev/learn/mounjaro-vs-zepbound-2026/</id><link href="https://dosepace.pages.dev/learn/mounjaro-vs-zepbound-2026/"/><updated>2026-09-03T00:00:00Z</updated><author><name>Capy Editorial Team</name></author><summary>Mounjaro and Zepbound both contain tirzepatide, but their FDA-labeled uses are not identical. Here is what that distinction means for accurate records.</summary></entry><entry xml:lang="en-US"><title>Compounded GLP-1 Products in 2026: What the FDA Says</title><id>https://dosepace.pages.dev/learn/compounded-glp-1-fda-2026/</id><link href="https://dosepace.pages.dev/learn/compounded-glp-1-fda-2026/"/><updated>2026-09-03T00:00:00Z</updated><author><name>Capy Editorial Team</name></author><summary>A concise review of FDA statements about compounded semaglutide and tirzepatide, approval status, dosing-error reports, and changing shortage policies.</summary></entry><entry xml:lang="es-MX"><title>Medicamentos GLP-1 en México: alertas y anuncios irregulares</title><id>https://dosepace.pages.dev/es-mx/guias/mexico-alertas-glp-1-cofepris/</id><link href="https://dosepace.pages.dev/es-mx/guias/mexico-alertas-glp-1-cofepris/"/><updated>2026-09-03T00:00:00Z</updated><author><name>Capy Editorial Team</name></author><summary>Cómo consultar información oficial de COFEPRIS sobre medicamentos GLP-1, publicidad irregular, registros y farmacovigilancia en México.</summary></entry><entry xml:lang="pt-BR"><title>Canetas GLP-1 no Brasil: retenção da receita em 2026</title><id>https://dosepace.pages.dev/pt-br/guias/brasil-glp-1-retencao-receita-anvisa/</id><link href="https://dosepace.pages.dev/pt-br/guias/brasil-glp-1-retencao-receita-anvisa/"/><updated>2026-09-03T00:00:00Z</updated><author><name>Capy Editorial Team</name></author><summary>Entenda a regra da Anvisa para prescrição e dispensação de agonistas GLP-1 no Brasil, sem orientações de dose ou tratamento.</summary></entry><entry xml:lang="es-ES"><title>Medicamentos GLP-1 por internet en España: qué advierten AEMPS y EMA</title><id>https://dosepace.pages.dev/es-es/guias/espana-medicamentos-glp-1-ilegales-internet/</id><link href="https://dosepace.pages.dev/es-es/guias/espana-medicamentos-glp-1-ilegales-internet/"/><updated>2026-09-03T00:00:00Z</updated><author><name>Capy Editorial Team</name></author><summary>AEMPS y EMA alertan sobre medicamentos GLP-1 ilegales vendidos por internet. Aprende a distinguir información oficial de una oferta fraudulenta.</summary></entry><entry xml:lang="ar-SA"><title>أدوية GLP-1 الفموية في السعودية عام 2026: ماذا أعلنت هيئة الغذاء والدواء؟</title><id>https://dosepace.pages.dev/ar-sa/guides/saudi-arabia-oral-glp-1-sfda-2026/</id><link href="https://dosepace.pages.dev/ar-sa/guides/saudi-arabia-oral-glp-1-sfda-2026/"/><updated>2026-09-03T00:00:00Z</updated><author><name>Capy Editorial Team</name></author><summary>ملخص محايد لإعلان هيئة الغذاء والدواء السعودية عن تسجيل مستحضر فموي من فئة GLP-1، وما يعنيه ذلك لسجل دوائي دقيق.</summary></entry></feed>